Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hangzhou Jiyuan Gene Technology

Request full access

Committed to applying modern leading gene technology to develop innovative cellular immune products, focusing on the treatment of malignant tumors

ChinaFounded 2020Biotech & Life Sciences

About Hangzhou Jiyuan Gene Technology

Hangzhou Jiyuan Gene Technology Co., Ltd. (Celgenyx Bio) is a biopharmaceutical company established in 2020, founded by a group of senior American-educated scholars, entrepreneurs, and venture capitalists. The firm is strategically focused on the application of modern genetic technologies to develop and commercialize cell immunotherapy products specifically for the treatment of malignant tumors.

The company operates as a private, venture-capital-backed entity and has secured significant funding to advance its pipeline. A notable milestone was the completion of a 100 million yuan Series A financing round in 2022, led by the international investment firm Vivo Capital. This capital infusion supports the progression of its product candidates toward clinical application and industrialization. The company has established a comprehensive infrastructure in Hangzhou's Qiantang New District, which includes a research and development center, a GMP-compliant production workshop, and a quality control center, all of which became operational in 2021.

Celgenyx Bio's business model is centered on the research, development, and eventual sale of its proprietary cell therapy products. The company leverages a sophisticated technology suite that encompasses multiple platforms, including hybridoma antibody technology, antibody humanization, human antibody phage display, and CAR vector construction with lentiviral vector preparation. Furthermore, it has developed capabilities in human induced pluripotent stem cells (iPSC), covering their induction, identification, preparation, and gene editing. Through strategic partnerships and patent licensing, Celgenyx Bio has secured the rights to multiple global patents and in-licensed products for development and commercialization within the Greater China region, working closely with international research institutions and its U.S.-based affiliate, Celgenyx USA.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
21.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Oct 2022 $14M $55M Vivo Capital ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Hangzhou Jiyuan Gene Technology website traffic

Latest recorded traffic for Hangzhou Jiyuan Gene Technology is 190 monthly website visits, down 9.5% over the last three months.

Latest monthly visits190 3-month web change-9.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Hangzhou Jiyuan Gene Technology in its local ecosystem

Live from Dealroom

The Hangzhou Jiyuan Gene Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hangzhou Jiyuan Gene Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hangzhou Jiyuan Gene Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.